CD274 and gastric cancer: In total, 1581 patients with previously untreated advanced GC/GEJC/EAC were randomized to receive nivolumab plus chemotherapy or chemotherapy in the CheckMate 649 study; of these patients, 1297 had PD-L1 CPS ≥ 1 and 955 had PD-L1 CPS ≥ 5.